scholarly journals Cardiovascular ultrashort echo time to map fibrosis—promises and challenges

2019 ◽  
Vol 92 (1103) ◽  
pp. 20190465
Author(s):  
Joanne D Schuijf ◽  
Bharath Ambale-Venkatesh ◽  
Yoshimori Kassai ◽  
Yoko Kato ◽  
Larry Kasuboski ◽  
...  

Increased collagen, or fibrosis, is an important marker of disease and may improve identification of patients at risk. In addition, fibrosis imaging may play an increasing role in guiding therapy and monitoring its effectiveness. MRI is the most frequently used modality to detect, visualize and quantify fibrosis non-invasively. However, standard MRI techniques used to phenotype cardiac fibrosis such as delayed enhancement and extracellular volume determination by T1 mapping, require the administration of gadolinium-based contrast and are particularly difficult to use in patients with cardiac devices such as pacemakers and automatic defibrillators. Therefore, such methods are limited in the serial evaluation of cardiovascular fibrosis as part of chronic disease monitoring. A method to directly measure collagen amount could be of great clinical benefit. In the current review we will discuss the potential of a novel MR technique, ultrashort echo time (UTE) MR, for fibrosis imaging. Although UTE imaging is successfully applied in other body areas such as musculoskeletal applications, there is very limited experience so far in the heart. We will review the established methods and currently available literature, discuss the technical considerations and challenges, show preliminary in vivo images and provide a future outlook on potential applications of cardiovascular UTE.

2018 ◽  
Vol 49 (5) ◽  
pp. 1475-1488 ◽  
Author(s):  
Aaryani Tipirneni-Sajja ◽  
Ralf B. Loeffler ◽  
Axel J. Krafft ◽  
Andrea N. Sajewski ◽  
Robert J. Ogg ◽  
...  

2020 ◽  
Vol 33 (10) ◽  
Author(s):  
Ya‐Jun Ma ◽  
Adam C. Searleman ◽  
Hyungseok Jang ◽  
Shu‐Juan Fan ◽  
Jonathan Wong ◽  
...  

Blood ◽  
2020 ◽  
Author(s):  
Akash Gupta ◽  
Yu-Dong Fei ◽  
Tae Yun Kim ◽  
An Xie ◽  
Ken Batai ◽  
...  

Previous reports indicate IL18 is a novel candidate gene for diastolic dysfunction in sickle cell disease (SCD)-related cardiomyopathy. We hypothesize that IL-18 mediates the development of cardiomyopathy and ventricular tachycardia (VT) in SCD. Compared to control (CTR) mice, a "humanized" mouse model of SCD exhibited increased cardiac fibrosis, prolonged action potential duration (APD), higher VT inducibility in vivo, higher cardiac NFκB phosphorylation and circulating IL-18 levels, as well as reduced voltage-gated potassium channel expression, translating to reduced outward potassium current (Ito) in isolated cardiomyocytes. IL-18 administration to isolated mice hearts resulted in VTs, originating from the right ventricle, and further reduced Ito in SCD mice cardiomyocytes. Sustained IL-18 inhibition via IL-18 binding protein resulted in decreased cardiac fibrosis and NFκB phosphorylation, improved diastolic function, normalized electrical remodeling and attenuated IL-18-mediated VT in SCD mice. Patients with SCD and either myocardial fibrosis or increased QTc displayed greater IL18 gene expression in peripheral blood mononuclear cells (PBMC), with QTc strongly correlated with plasma IL-18 levels. PBMC-derived IL18 gene expression was increased in non-surviving over surviving subjects. IL-18 is a mediator of sickle cell cardiomyopathy and VT in mice and a novel therapeutic target in patients at risk for sudden death.


Radiology ◽  
2008 ◽  
Vol 248 (3) ◽  
pp. 824-833 ◽  
Author(s):  
Aranee Techawiboonwong ◽  
Hee Kwon Song ◽  
Mary B. Leonard ◽  
Felix W. Wehrli

2018 ◽  
Vol 81 (3) ◽  
pp. 1634-1644 ◽  
Author(s):  
Ya‐Jun Ma ◽  
Wei Zhao ◽  
Lidi Wan ◽  
Tan Guo ◽  
Adam Searleman ◽  
...  

2016 ◽  
Vol 77 (5) ◽  
pp. 1831-1840 ◽  
Author(s):  
Charles R. Castets ◽  
William Lefrançois ◽  
Didier Wecker ◽  
Emeline J. Ribot ◽  
Aurélien J. Trotier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document